AMGEN INC
AMGNNasdaq · SIC 2836
$366.29
↓ -1.4%Jul 17 close · end-of-day
Price
1Y↑ +26.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$199.3B
Enterprise Value
$244.5B
P/E
25.5
P/S
5.4
P/B
21.7
EV/EBITDA
15.8
PEG
4.6
FCF Yield
4.3%
Dividend Yield
2.7%
Revenue (TTM)
$37.2B
Net Income (TTM)
$7.8B
Free Cash Flow (TTM)
$8.6B
Gross Margin
—
Operating Margin
28.4%
Net Margin
21.0%
ROE
84.9%
ROIC
16.7%
Debt / Equity
6.2
Net Cash
-$45.3B
Return 1Y
+26.5%
Company profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- CEO
- Robert A. Bradway
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 25,200
- Headquarters
- California
- Website
- amgen.com
Management & directors
- Bradner James E.EVP, Research and Development
- Bradway Robert AChairman, CEO and President
- Busch Matthew C.VP, Finance & CAO
- Gordon MurdoEVP, Global Commercial Ops
- Graham Jonathan PEVP & Gen. Counsel & Sec.
- Griffith Peter H.EVP & CFO
- Grygiel Nancy A.SVP & CCO
- Khosla RachnaSVP, Business Development
- Miller DerekSVP, Human Resources
- Reese David MEVP & Chief Technology Officer
- Santos EstebanEVP, Operations
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-30
AMGN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$8.6B↑ +5.8%
Diluted EPS$3.34↑ +4.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $25.4B | $26.0B | $26.3B | $28.2B | $33.4B | $36.8B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $9.1B | $7.6B | $9.6B | $7.9B | $7.3B | $9.1B |
| Net income | $7.3B | $5.9B | $6.6B | $6.7B | $4.1B | $7.7B |
| Diluted EPS | $12.31 | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 |
| Operating cash flow | $10.5B | $9.3B | $9.7B | $8.5B | $11.5B | $10.0B |
| Free cash flow | $9.9B | $8.4B | $8.8B | $7.4B | $10.4B | $8.1B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 35.9% | 29.4% | 36.3% | 28.0% | 21.7% | 24.7% |
| Net margin | 28.6% | 22.7% | 24.9% | 23.8% | 12.2% | 21.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.4B | $8.5B | $9.1B | $8.1B | $9.2B | $9.6B | $9.9B | $8.6B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $1.9B | $2.0B | $2.3B | $1.2B | $2.7B | $2.5B | $2.7B | $2.7B |
| Net income | $746.0M | $2.8B | $627.0M | $1.7B | $1.4B | $3.2B | $1.3B | $1.8B |
| Diluted EPS | $1.38 | $5.22 | $1.17 | $3.20 | $2.65 | $5.93 | $2.45 | $3.34 |
| Operating cash flow | $2.5B | $3.6B | $4.8B | $1.4B | $2.3B | $4.7B | $1.6B | $2.2B |
| Free cash flow | $2.2B | $3.3B | $4.4B | $980.0M | $1.9B | $4.2B | $961.0M | $1.5B |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 22.8% | 24.1% | 25.4% | 14.5% | 28.9% | 26.4% | 27.6% | 30.9% |
| Net margin | 8.9% | 33.3% | 6.9% | 21.2% | 15.6% | 33.7% | 13.5% | 21.1% |
Company news
Jul 20, 2026
- 2h agoMerck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.finance.yahoo.com
- 3h agoEli Lilly Stock And The Price Of Confidencetrefis.com
- 8h agoAmgen Earnings Preview: What to Expectbarchart.com
- 15h agoWhat Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.finance.yahoo.com
Jul 17, 2026
- 3d agoStock Market Today: Dow, Nasdaq Slide As Oil Climbs, Netflix Tumbles; Eli Lilly In Buy Zone (Live Coverage)finance.yahoo.com
- 3d agoThe First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?247wallst.com
- 3d agoThe $5.25 billion ETF paying dividends that grew three years straight right now247wallst.com
- 3d agoSeagate Stock And The Bet On A Denser Futuretrefis.com
- 3d agoZenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Saysfinance.yahoo.com
- 3d agoFortinet Stock Is Pricing In A Much Bigger Futuretrefis.com
- 3d agoThe weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Ideafinance.yahoo.com
Jul 16, 2026
- 4d agoMerck Snags A First-Of-Its-Kind Approval, And Shares Jumpfinance.yahoo.com
- 4d agoMerck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pillfinance.yahoo.com
- 4d agoWill Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?finance.yahoo.com
- 4d agoEli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billionfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-19 | MILES AMY E | Award | 665 | $0.00 | $0.00 | filing |
| 2026-05-19 | Kullman Ellen Jamison | Award | 665 | $0.00 | $0.00 | filing |
| 2026-05-19 | Klotman Mary E. | Award | 665 | $0.00 | $0.00 | filing |
| 2026-05-19 | Jacks Tyler | Award | 665 | $0.00 | $0.00 | filing |
| 2026-05-19 | ISHRAK OMAR | Award | 665 | $0.00 | $0.00 | filing |
| 2026-05-19 | HOLLEY CHARLES M | Award | 665 | $0.00 | $0.00 | filing |
| 2026-05-19 | Garland Greg C. | Award | 665 | $0.00 | $0.00 | filing |
| 2026-05-19 | ECKERT ROBERT | Award | 665 | $0.00 | $0.00 | filing |
| 2026-05-19 | Druker Brian | Award | 665 | $0.00 | $0.00 | filing |
| 2026-05-19 | Drake Michael V | Award | 665 | $0.00 | $0.00 | filing |
| 2026-05-19 | Austin Wanda M | Award | 665 | $0.00 | $0.00 | filing |
| 2026-05-07 | Bradway Robert A· Chairman, CEO and President | Tax withholding | 2,079 | $331.11 | $688,377.69 | filing |
| 2026-05-07 | Gordon Murdo· EVP, Global Commercial Ops | Tax withholding | 615 | $331.11 | $203,632.65 | filing |
| 2026-05-07 | Griffith Peter H.· EVP & CFO | Tax withholding | 556 | $331.11 | $184,097.16 | filing |
| 2026-05-07 | REESE DAVID M· EVP & Chief Technology Officer | Tax withholding | 556 | $331.11 | $184,097.16 | filing |
| 2026-05-07 | Santos Esteban· EVP, Operations | Tax withholding | 522 | $331.11 | $172,839.42 | filing |
| 2026-05-07 | Graham Jonathan P· EVP & Gen. Counsel & Sec. | Tax withholding | 499 | $331.11 | $165,223.89 | filing |
| 2026-05-07 | Bradner James E.· EVP, Research and Development | Tax withholding | 446 | $331.11 | $147,675.06 | filing |
| 2026-05-07 | Miller Derek· SVP, Human Resources | Tax withholding | 151 | $331.11 | $49,997.61 | filing |
| 2026-05-07 | Khosla Rachna· SVP, Business Development | Tax withholding | 93 | $331.11 | $30,793.23 | filing |
| 2026-05-07 | Grygiel Nancy A.· SVP & CCO | Tax withholding | 88 | $331.11 | $29,137.68 | filing |
| 2026-05-07 | Busch Matthew C.· VP, Finance & CAO | Tax withholding | 41 | $331.11 | $13,575.51 | filing |
| 2026-05-06 | Bradway Robert A· Chairman, CEO and President | Tax withholding | 1,702 | $329.59 | $560,962.18 | filing |
| 2026-05-06 | Griffith Peter H.· EVP & CFO | Tax withholding | 502 | $329.59 | $165,454.18 | filing |
| 2026-05-06 | Gordon Murdo· EVP, Global Commercial Ops | Tax withholding | 502 | $329.59 | $165,454.18 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.